Login to Your Account

Sage on fire as phase II win makes GABAA's case in MDD

By Randy Osborne
Staff Writer

Thursday, December 7, 2017

"There was always a question of whether or not there was something special about brexanolone," Sage Therapeutics Inc.'s chief medical officer (CMO), Steve Kanes, told BioWorld, referring to the phase III win in post-partum depression (PPD) last month. "It doesn't seem to be the case."

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription